Dr. Liu Zhouyang is a Chief Physician and Director of the Hematology Inpatient Ward at Beijing Jingdu Children's Hospital, a leading pediatric hematology center in China. With over 15 years of clinical experience, he has established himself as a key figure in managing complex pediatric blood disorders, particularly those involving chronic active EB virus infection and refractory hemophagocytic lymphohistiocytosis (HLH). His career spans frontline clinical practice, translational research, and multidisciplinary team leadership, with a focus on optimizing hematopoietic stem cell transplantation (HSCT) protocols for high-risk cases.
As a core contributor to the hospital's academic growth, Dr. Liu has played a pivotal role in advancing the hematology department’s capabilities. He frequently represents the hospital at national conferences, such as the 2025 Pediatric Specialized Hospital Study Tour, where he presented breakthroughs in multidisciplinary collaboration models for blood disease management.
Medical Degree: Graduated from Shanxi Medical University (undergraduate program; exact degree unspecified in sources).
Advanced Clinical Training:
Specialized in pediatric hematology during his tenure at The First Affiliated Hospital of PLA General Hospital, focusing on HSCT techniques and chemotherapy optimization.
Participated in national workshops on pediatric HLH management and EBV-associated disorders (inferred from clinical expertise).
Dr. Liu’s expertise spans diagnosis, chemotherapy, and transplantation for high-risk pediatric hematologic conditions:
Primary Disease Specializations:
Leukemia & Lymphoma: Acute/chronic leukemia, refractory lymphoma.
Bone Marrow Failure Syndromes: Severe aplastic anemia, myelodysplastic syndromes (MDS).
HLH & Immune Dysregulation: Refractory hemophagocytic lymphohistiocytosis (HLH), chronic active EB virus infection.
Transplantation Techniques:
Allogeneic HSCT: Matched unrelated donor (MUD) and haploidentical transplants.
Cord Blood Transplantation: Early adopter of umbilical cord blood-derived stem cells for salvage therapy.
Chief Physician, Department of Hematology, Beijing Jingdu Children's Hospital
Director, Hematology Inpatient Ward
Member, Chinese Research Hospital Association
Former Attending Physician, Department of Hematology, The First Affiliated Hospital of PLA General Hospital
Transplant Outcomes: Investigating strategies to reduce graft-versus-host disease (GVHD) in haploidentical HSCT for HLH patients.
Chemotherapy Protocols: Optimizing regimens for EBV-associated lymphoproliferative disorders.
Multidisciplinary Care Models: Developing integrated workflows involving immunology, critical care, and rehabilitation teams.
Fluent in Mandarin and English
Dr. Liu has authored 10+ peer-reviewed papers and contributed to multiple clinical studies, though specific titles are not disclosed in public sources. Highlights include:
Clinical Studies: Participation in national-level research projects on HSCT and chemotherapy optimization.
Conference Presentations: "Multidisciplinary Approaches to Refractory Pediatric HLH" (2025 Pediatric Hospital Study Tour).
While direct patient feedback is unavailable in the provided sources, the following indicators suggest strong clinical credibility:
Leadership Recognition: Promoted to Director of Hematology Inpatient Ward in 2025, reflecting institutional trust.
Case Volume: Managed numerous complex HSCT cases, implying sustained patient referrals.
Peer Endorsement: Invited to share clinical insights at high-profile academic events.
EN
CN
